MedTrace Logo

Multimodal Biomarkers for Diagnosis and Prognosis in VCI

NCT04604600 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-10-27

No results posted yet for this study

Summary

We will try to

1. establish the correlation of plasma Aβ40 and Aβ42 level, ApoE genotype, MRI imaging markers in the diagnosis and prognosis of VCI patients
2. understand more on the pathophysiology of VCI.

Conditions

  • Vascular Cognitive Impairment
  • Alzheimer Disease

Interventions

DRUG

amyloid PET

Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-03
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604600 on ClinicalTrials.gov